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Abstract 
Breast cancer in men is relatively rare and its coexistence with other primary non-breast 
cancers exceptional. Here, we report the case of a 50-year-old man who presented with 
symptoms of rectal adenocarcinoma and in whom a synchronous, asymptomatic cancer 
of the left breast was found incidentally at physical examination. 
 
Introduction 
Male breast cancer is relatively rare, accounting for about 1% of all breast cancer cases 
with an incidence of approximately 1 per 100,000 men per year [1]. Genetic, hormonal 
and environmental factors involved in female breast carcinogenesis also play a role in the 
etiology of male breast cancer [2]. Women with breast cancer have an increased risk of 
developing a second, breast or non-breast, malignancy and the same appears to apply to 
male breast cancer patients [3]. Here, we report a rare case of synchronous presentation of 
breast and rectal cancer in a man. 
Case Report 
A 50-year-old man presented with a one-month history of rectal bleeding, chronic constipation, 
weight loss of 10 kg over the last 3 months but no appetite loss. He had arterial hypertension treated 
with furosemide, but otherwise his past medical history and family history were unremarkable. Physical 
examination revealed a fit man. His body weight was 100 kg and the body mass index was 31.21 kg/m
2. 
His abdomen was soft, with normal bowel sounds, no distension, and no palpable masses. Rectal 
examination revealed an easily bleeding, 4-cm polypoid mass confined to the anterior wall, about 6 cm Case Rep Oncol 2011;4:281–286 
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from the anal verge. Routine physical examination of the breast revealed an asymptomatic, painless, 
well-circumscribed, hard but mobile nodule of 3 cm in diameter below the left nipple. The contralateral 
breast was normal and there was no evident gynecomastia. Supraclavicular or axillary lymph nodes were 
not palpable. Laboratory tests, complete blood count, blood biochemistry and tumor markers (CEA, 
CA19-9 and CA15-3) were all within normal limits. Total flexible colonoscopy confirmed the presence 
of a rectal tumor whose biopsy revealed a well-differentiated adenocarcinoma. There were no other 
lesions in the entire colon. Mammography and computed tomography suggested carcinoma of the left 
breast and this was confirmed by fine needle aspiration biopsy (fig. 1, fig. 2). Abdominal and thoracic 
computed tomography and whole body bone scintigraphy excluded distal metastases. 
The patient underwent low anterior resection of the rectum along with total mastectomy and axillary 
lymph node dissection. Histological analysis revealed a well-differentiated adenocarcinoma of the 
rectum infiltrating the muscularis propria. There were no lymph node or distant metastases and the 
tumor was assigned as stage I (T2N0M0) according to the sixth edition of the TNM system (2002). 
Histological analysis of the breast tumor showed a poorly differentiated, histological grade III, not 
otherwise specified, infiltrating ductal carcinoma, measuring 3 cm in diameter. Ductal carcinoma in situ 
components of cribriform and comedo type were also detected. Immunostaining for both estrogen and 
progesterone receptors showed strong positivity whilst the expression of c-erbB-2 (Her-2/neu) was 
negative. There was no evidence of metastatic disease in the axillary lymph nodes and therefore, the 
tumor was staged as IIA (T2N0M0) according to the TNM system of the International Union against 
Cancer. The genetic testing for BRCA2 mutation showed no abnormality. 
The case was presented to the Tumor Board of our institution and the decision was made to 
administer systemic chemotherapy followed by hormonotherapy for the breast cancer. This decision 
was based on the size of the tumor (3-cm lesion) and its poor differentiation. Adjuvant treatment for the 
rectal cancer was not recommended because both chemotherapy and radiotherapy have not been shown 
to be of any benefit for stage I colorectal cancers. The patient started combination chemotherapy 
consisting of paclixatel at a dose of 175 mg/m
2 plus capecitabine at a dose of 2,000/m
2 orally for 14 
consecutive days for six cycles repeated every 21 days. The treatment was well tolerated and at its 
completion, the patient was given oral anti-estrogen treatment (tamoxifen 20 mg once daily for 5 years) 
and a standard follow-up was recommended. The last follow-up was 16 months after surgery and the 
patient remains clinically well, without evidence of locoregional or distant recurrence of either cancers. 
Discussion 
Breast cancer in men is uncommon. Genetic, hormonal and environmental factors are 
involved in its pathogenesis, with 15–20% of cases being hereditary, occurring mostly in 
men with germ-line mutations in the BRCA2 gene, whereas BRCA1 gene mutations are 
not associated with increased breast cancer susceptibility in men [2]. Risk factors like age, 
testicular disease, benign breast conditions, family history, Klinefelter’s syndrome, liver 
cirrhosis, chest wall irradiation, hormonal treatment, obesity and alcohol consumption 
have also been implicated in male breast carcinogenesis. In our patient, no apparent risk 
factors were noted and the rectal tumor was assumed as sporadic rectal cancer. Our 
patient presented with an adenocarcinoma of the rectum, and an invasive ductal 
carcinoma of the left breast was diagnosed incidentally at the same time. Only one similar 
report has been detected in the literature where a synchronous breast cancer was found 
incidentally in a 72-year-old patient with sigmoid colon cancer [4]. Nevertheless, it is not 
clear which tumor was preceding the other one. 
The risk of second malignancy among female breast cancer patients has been studied 
extensively, but very few studies have assessed the risk of second cancer, either breast or 
non-breast, among male breast cancer patients or the risk for developing breast cancer 
following any other primary cancer. Male patients had a 93-fold (95% confidence interval 
(CI): 39.0–184) increased risk of developing a second breast cancer, the standardized Case Rep Oncol 2011;4:281–286 
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incidence ratio (SIR) being highest (SIR: 111.7, 95% CI: 10.5–410.9) in patients more than 
10 years after the diagnosis of the primary breast cancer [5]. In a cohort of 404 men with 
breast cancer, 2.7% of them subsequently developed either synchronous or metachronous 
contralateral breast cancer, whereas 17% of them developed a second non-breast 
malignancy, mainly prostate, lung, colorectal and esophageal cancer [6]. Data from the 
California Cancer Registry on 1,926 men with a first primary breast cancer showed that 
11.5% of them developed a second primary cancer. The risk of developing a second cancer 
was mostly elevated for breast cancer (SIR: 52.12, 95% CI: 31.83–80.49), cutaneous 
melanoma (SIR: 2.98, 95% CI: 1.63–5.00) and gastric cancer (SIR: 2.11, 95% CI: 1.01–
3.88), and there was a tendency towards higher risks of second malignancies among 
younger men compared to older men with the risk increasing over time [7]. Conversely, 
data from 1,788 men with breast cancer registered with the Surveillance, Epidemiology 
and End Results (SEER) Program showed no increase in the overall subsequent non-
breast cancer risk [8]. However, a 30-fold increased risk (SIR: 29.64, 95% CI: 15–52) of 
developing subsequent contralateral breast cancer was found. The risk was much higher 
(SIR: 110.29, 95% CI: 13.33–401.32) for those diagnosed with their primary breast cancer 
before the age of 50 years [8]. Pooled data on 3,409 men with primary breast cancer from 
13 large cancer registries showed that 12.5% of patients subsequently developed a second 
cancer other than breast cancer [9]. The risk was higher for cancers of the small intestine, 
pancreas or prostate, myeloid leukemia, non-melanoma skin cancer, and cancer of the 
lymphohematopoietic system. Data from 225 male breast cancers detected after any other 
primary neoplasm showed that the risk of developing breast cancer was higher after 
lymphohematopoietic neoplasms (SIR: 1.80, 95% CI: 1.07–2.84), mainly multiple 
myeloma (SIR: 3.77, 95% CI: 1.03–9.65), and after prostate cancer (SIR: 1.19, 95% CI: 
0.90–1.54), mostly 1–9 years after prostate cancer diagnosis (SIR: 1.45, 95% CI: 1.07–
1.92). The risk of subsequent colorectal (SIR: 1.35, 95% CI: 1.02–1.76) or rectal (SIR: 1.78, 
95% CI: 1.20–2.54) cancer development was elevated, occurring mostly in older patients 
(diagnostic age for breast cancer over 75 years) after 1–9 years of follow-up. 
A number of population-based studies evaluated the association between breast and 
colorectal cancer in the reverse direction, namely the risk of second primary non-
colorectal cancer occurring after colorectal adenocarcinoma [10–15]. The incidence of 
synchronous or metachronous non-colorectal cancer was 2–6%. The most common 
malignancies seen were cancer of the stomach, especially in countries with a high 
incidence of gastric cancer, intestinal, kidney, prostate, uterine, cervical and ovarian 
cancer [10–15]. The majority of those secondary malignancies developed within 3 years 
after the primary colorectal cancer, although some developed 5 years or more after the 
initial diagnosis of colorectal cancer. Regarding breast cancer, Ueno et al. [10] reported 
that when colon cancer was associated with other cancers in women, the most frequently 
encountered neoplasm was gastric cancer (1.4%) followed by breast cancer (0.4%). Similar 
results were reported by Kan et al. [12]. An increased risk of developing breast cancer in 
women who survived colorectal cancer was also reported [11]. However, Evans et al. [14], 
after evaluating 61,433 men and 65,848 women with cancer included in the Thames 
Cancer Registry, failed to detect an increased risk for breast cancer development after 
diagnosis of colorectal cancer in women and there were no cases of breast cancer in the 
male cohort. When data on 262,600 cases of colorectal cancer from the SEER Program 
were assessed for the occurrence of subsequent primary cancers, it was found that the 
significantly increased risk of developing breast cancer after colorectal cancer in women 
was valid only for cancers reported during the first 5 months of follow-up (suggesting Case Rep Oncol 2011;4:281–286 
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synchronous lesions), whereas the risk of metachronous cancer was not elevated and 
again no cases of male breast cancer were found [15]. 
Differences among cancer registries regarding cohort characteristics, disease reporting, 
synchronous or metachronous definition, length of follow-up and coding policy may 
account at least in part for the variation in results. Apparently, multifocal cancers may 
occur; however, an elevated risk of synchronous cancers among persons with colorectal 
carcinoma could be attributed to ‘lead time bias’ since second tumors might be detected 
before becoming clinically apparent because of increased medical scrutiny. In addition, 
when two cancers are diagnosed at the same time, the primary cancer may be defined 
arbitrarily as in our patient, who presented with symptoms from the rectal cancer, 
whereas the breast cancer was diagnosed incidentally during routine clinical examination. 
In this patient, the association between a frequent cancer-like rectal cancer and breast 
cancer cannot be explained by genetic alterations, environmental or other risk factors, 
and mechanisms of carcinogenesis shared by these two cancers. Data from the 
aforementioned population studies precluded a bidirectional association between breast 
and colorectal cancer, and a causal relationship between them cannot be demonstrated. A 
modestly increased risk of subsequent second colonic or rectal cancer was found in older 
males with breast cancer in the long-term follow-up but not vice versa, implying different 
etiologies for these two cancers. The synchronous rectal cancer in our patient was 
probably sporadic (since there was no polyposis of the large bowel and his family history 
for colorectal or other cancers was negative) and would have occurred in the absence of 
breast cancer. Although there were no BRCA2 mutations, alterations in the expression 
and function of other as yet unknown genes can not be excluded. In this context, the 
frame-shift mutation 1100delC in the cell cycle checkpoint kinase 2 gene (CHEK2) has 
been reported to be a low-penetrance breast cancer-predisposing gene associated with a 
three- to five-fold increased risk of breast cancer [16]. Recent studies have shown that the 
1100delC variant of CHEK2 confers also a colorectal cancer risk in hereditary non-
polyposis colorectal cancer (HNPCC) and HNPCC-related families [17, 18]. These 
findings suggest that CHEK2 is a multiorgan cancer susceptibility gene acting probably in 
synergy with other susceptibility genes. Its function as a ‘breast-colon cancer’ gene, either 
by conferring a high risk of one cancer type and a slightly increased risk of the other or 
through a predisposition to one of the two cancers and chance occurrence of the other, 
may explain the simultaneous occurrence of breast and colorectal cancer in ‘breast-colon 
cancer’ patients [19]. When two primary cancers are diagnosed simultaneously, the 
systemic treatment should be directed against the tumor with worst prognosis. In our 
patient, systemic chemotherapy for breast cancer was administered because of the more 
advanced stage compared to the rectal cancer. Adjuvant treatment for the rectal cancer 
was not given because neither chemotherapy nor radiotherapy has shown any benefit for 
stage I colorectal cancer. 
We conclude that male breast cancer patients may develop, either synchronously or 
metachronously, a second non-breast primary cancer such as colorectal cancer, and this 
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Fig. 2. Thoracic CT scan showing a mass in the left breast. 
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